Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05800587 · ClinicalTrials.gov registry record · Phase 2
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 1
- Study location
NCT05800587: Recruiting Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Fox Chase Cancer Center.
NCT05800587 is a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 280 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05800587, a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.
Primary Outcome
To estimate the ORR including confirmed complete response (CR) and partial response (PR) rates in each treatment group 1-3
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Nab paclitaxel
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2023-02-22 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 2 |
What NCT05800587 shows while recruiting
NCT05800587 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (57% lower).
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05800587 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05800587 about?
NCT05800587 is a clinical study titled "Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer". This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.
What is the current status of trial NCT05800587?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2023-02-22. Estimated completion is 2029-08-01.
What conditions does trial NCT05800587 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Small-cell Lung Cancer.
What interventions are being tested in trial NCT05800587?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Nab paclitaxel (DRUG).
Who is sponsoring clinical trial NCT05800587?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05800587 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05800587's enrollment target sits among peer trials
280 133rd of 454 higher than 321 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI